503A vs. 503B Compounding Pharmacies: What's the Difference, and Does It Matter?

503A and 503B are not two quality grades. They are two different federal pathways for drug compounding under the Federal Food, Drug, and Cosmetic Act.

A 503A pharmacy generally compounds medications for an identified individual patient based on a prescription, with state boards of pharmacy handling most day-to-day oversight.

A 503B outsourcing facility registers with the FDA, must follow federal current good manufacturing practice requirements (CGMP), is subject to risk-based FDA inspections, and can compound qualifying products without necessarily having a patient-specific prescription in hand.

The most important point: neither pathway makes a compounded drug FDA approved.

503A vs. 503B: What Actually Changes?

Drug compounding is the preparation of a medication to meet a medical need that an available FDA-approved product does not.

The FDA gives examples such as making a medication without a dye for someone with an allergy or preparing a liquid formulation for someone who cannot swallow a tablet. Compounding may also be permitted in certain drug-shortage situations when federal conditions are met.

But an FDA-approved medication and a compounded medication are not the same thing. The FDA does not review each compounded product before marketing for safety, effectiveness, and quality in the same way it reviews an approved drug.

What Is a 503A Compounding Pharmacy?

Section 503A generally covers qualifying compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician.

Its defining feature is the patient-specific model. Compounding generally must be based on a valid prescription for an identified individual patient. Limited anticipatory compounding is allowed when there is an established history of receiving valid prescriptions for that drug.

State boards of pharmacy generally handle day-to-day oversight of state-licensed pharmacies that are not registered outsourcing facilities, although the FDA retains federal authority.

When Section 503A conditions are met, the compounding is exempt from federal Current Good Manufacturing Practice (CGMP) requirements. That does not mean there are no quality standards: state pharmacy requirements and other applicable federal provisions still apply.

What Is a 503B Outsourcing Facility?

Section 503B created a separate category known as an outsourcing facility.

A 503B facility registers with the FDA and can compound qualifying products without necessarily having prescriptions for identified individual patients. This allows models such as supplying office stock to healthcare providers, subject to Section 503B conditions and applicable state law.

In exchange for that flexibility, 503B outsourcing facilities must follow federal CGMP, are subject to FDA risk-based inspections, must report specified adverse events, and must provide the FDA with information about the products they compound.

503A vs. 503B: Side-by-Side Comparison

Is 503B Better Than 503A?

Not necessarily.

503B outsourcing facilities operate under additional federal manufacturing, inspection, and reporting requirements. Those are meaningful differences, but 503B is not simply a higher quality grade, and 503A should not be treated as a synonym for unsafe.

The two pathways serve different purposes: 503A centers on individualized patient compounding, while 503B supports a broader healthcare-supply model under additional federal requirements.

This is also why the phrase "FDA-registered" needs context.

FDA registration is not FDA approval. Registration does not mean the FDA has approved a facility's compounded medications or guaranteed that every product made there meets all applicable requirements.

503A vs. 503B for Compounded GLP-1 Medications

GLP-1 medications are a useful example of why the 503A or 503B label alone cannot tell you whether a particular drug can lawfully be compounded.

Both pathways restrict compounding copies of commercially available or FDA-approved drugs, and drug-shortage status can affect how those restrictions apply. For 503B outsourcing facilities, additional rules apply to bulk active pharmaceutical ingredients.

On April 1, 2026, the FDA stated that semaglutide and tirzepatide were on neither the drug shortage list nor the 503B bulks list.

On April 30, 2026, the FDA proposed not adding semaglutide, tirzepatide, or liraglutide to the bulks list. As of September 4, 2026, that action remained listed as a Federal Register proposal rather than a final determination.

That is why statements such as "503A can compound GLP-1s but 503B can't" are too broad.

Whether a specific instance of compounding qualifies under federal law can depend on the drug, shortage status, whether the compounded version is essentially a copy, the source and legal status of the active ingredient, an individual patient's clinical need, and other statutory conditions.

Safety reporting also differs. As of May 31, 2026, the FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.

The FDA cautions that these reports do not establish that the drug caused the reported event. It also believes adverse events involving compounded drugs may be underreported because ordinary state-licensed pharmacies do not carry the same federal reporting obligation as outsourcing facilities.

Five Questions to Ask Before Using a Compounded Medication

The fourth question is especially important for injectable medications.

The FDA has reported dosing errors involving compounded injectable semaglutide, including cases involving different product concentrations and confusion among milligrams, milliliters, and "units."

Some patients administered several times the intended dose, and some required medical attention or hospitalization.

Confirm exactly how to measure and administer your medication with your provider or compounder before the first dose.

How to Check a 503A Pharmacy or 503B Outsourcing Facility?

For a 503B outsourcing facility, the FDA maintains a Registered Outsourcing Facilities database.

As of August 28, 2026, it provides information including a facility's most recent registration, its last FDA inspection, whether a Form 483 was issued, recall information, and the action status from the most recent inspection.

Appearing in the database establishes registration, not FDA approval of every medication produced there.

For a 503A pharmacy, start with the relevant state board of pharmacy.

The FDA's BeSafeRx resource also links to state licensing databases and recommends checking that an online pharmacy is state-licensed, requires a prescription, provides a U.S. physical address and phone number, and has a licensed pharmacist available to answer questions.

The Bottom Line

"503A" and "503B" tell you something important about how a compounded medication is prepared, supplied, and regulated.

Neither label tells you whether that medication is right for you.

What am I taking? Why is it compounded? Who prepared it? What regulatory framework applies? And who can I contact when I have a question?

What Transparency Looks Like at Apsu

Before treatment, we tell you what you are being prescribed, why a compounded option is being considered, which pharmacy prepares it, and which regulatory pathway applies.

We provide the compounding pharmacy's name, state, and license or registration number, so you can verify it yourself before your first dose.

We also do not describe compounded medications as FDA approved — because they are not.

If questions come up, licensed clinical and pharmacy support is available through the same portal.

Prescription treatment requires a medical evaluation and clinical eligibility. Availability varies by state. Compounded medications are not FDA approved.

Start a consultation with a licensed provider. See our full disclosure on what we prescribe and who compounds it.

Sources